bms 37

BMS-37 is a PD-1/PD-L1 immune checkpoint inhibitor exhibiting IC50 values ranging from 18 to 200 nM against the PD-L1/PD-1 complex, while displaying nonspecific cytotoxicity toward modified Jurkat T cells with EC50 values between 3 and 6 μM, and it is widely used to investigate PD-L1–induced T-cell exhaustion mechanisms or as a PD-L1 ligand scaffold for the rational design and synthesis of PROTAC molecules in immuno-oncology research.

BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 80 nM.

BMS-378806 is an orally bioavailable HIV-1 inhibitor that interferes with gp120-CD4 interaction.

Fosravuconazole is a ravuconazole prodrug. It has antifungal activity.

BMS-378806 (BMS-806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.

Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate) is a broad-spectrum antifungal agent approved in Japan for treating onychomycosis, a fungal nail infection. It is a prodrug converted into ravuconazole.

AR ligand-37 is a PROTAC target protein ligand utilized in the synthesis of BMS-986365.